US Pat. No. 10,478,459

COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION

UNIVERSITE CATHOLIQUE DE ...

1. A combination comprising:a liquid cell suspension comprising adult liver-derived progenitor or stem cells and at least one factor Xa inhibitor which is a direct or indirect factor Xa inhibitor and is not an antithrombin activator, and
at least one thrombin inhibitor.
US Pat. No. 10,478,461

CELLULAR EXTRACTS

REGENICS AS, Oslo (NO)

1. A method of improving wound healing in a human subject, comprising:applying a composition comprising a trout egg cellular extract having a protein content of from about 210-270 mg/ml and an RNA content from about 3.51 to 4.68 mg/ml to a wound of said subject under conditions such wound healing is improved, wherein said improvement is selected from the group consisting of faster drying, faster reepithelialization, reduced inflammation, faster contraction, earlier remodeling, reduction in scar tissue and improved visual appearance of the wound and combinations thereof.
US Pat. No. 10,479,745

CATALYTIC ISOMERIZATION OF Z-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE TO E-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE

THE CHEMOURS COMPANY FC, ...

1. A process for isomerizing Z-1,1,1,4,4,4-hexafluoro-2-butene to E-1,1,1,4,4,4-hexafluoro-2-butene comprising:(a) providing a starting material comprising Z-1,1,1,4,4,4-hexafluoro-2-butene;
(b) contacting the starting material with a suitable catalyst in a reaction zone to produce E-HFO-1336mzz; and optionally,
(c) recovering the E-HFO-1336mzz,
wherein, when the contacting step is performed in the gas phase, the catalyst comprises chromium and less than 40% by weight alumina;
wherein when the contacting step is performed in the liquid phase, the catalyst comprises a metal halide wherein the metal halide is aluminum halide, antimony halide, tin halide, tantalum halide, titanium halide, niobium halide, molybdenum halide, iron halide, fluorinated chrome halide, or combinations thereof.
US Pat. No. 10,480,001

METHOD FOR THE GENERATION OF A MONOCLONAL PLANT CELL LINE

1. A method for the generation of a monoclonal plant cell line from a heterogeneous population of plant cells, comprising the following steps:(a) providing a heterogeneous population of plant cells;
(b) preparing a heterogeneous population of protoplasts from the heterogeneous population of plant cells, wherein at least one of the protoplasts from the prepared heterogeneous population of protoplasts is transformed with at least one expression vector encoding at least one fluorescent protein and a resistance against at least one selection agent;
(c) initiating cell wall regeneration in said heterogeneous population of protoplasts for fluorescence activated cell sorting (FACS);
(d) providing a cell deposition device containing feeder cells in liquid medium containing wells;
(e) sorting by FACS the prepared at least one protoplast from the heterogeneous population of protoplasts in which the cell wall regeneration has been initiated, wherein said at least one protoplast is highly fluorescent;
(f) separating the sorted at least one protoplast into at least one different liquid medium-containing well containing the feeder cells for monoclonal plant cell generation such that said at least one well for monoclonal plant cell line generation contains a single prepared protoplast permitted to directly contact the feeder cells;
(g) regenerating the single separated protoplast from said at least one well into a microcolony by co-cultivating the separated protoplast in the same well as the feeder cells; and
(h) removing the microcolony from the feeder cells and cultivating the microcolony in the presence of said at least one selection agent against which said at least one protoplast is transformed with said at least one expression vector encoding a resistance until a monoclonal plant cell line from said at least one protoplast is established.
US Pat. No. 10,478,464

COMPOSITIONS AND METHODS OF USE

Kirit Shah, Portland, OR...

1. A method of treating cancer in a subject comprising administering to the subject a composition comprising an effective amount of 8-hydroxyhexadecanoic acid, or a salt thereof, thereby treating said cancer;wherein said cancer is a lung cancer.
US Pat. No. 10,480,008

INSECTICIDAL POLYPEPTIDES HAVING BROAD SPECTRUM ACTIVITY AND USES THEREOF

POINEER HI-BRED INTERNATI...

1. An isolated nucleic acid molecule operably linked to a heterologous regulatory element, wherein said isolated nucleic acid is selected from the group consisting of:(a) a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 3;
(b) a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2 and SEQ ID NO: 4;
(c) a nucleic acid molecule comprising a nucleotide sequence encoding a protein, having insecticidal activity against soybean looper, comprising an amino acid sequence that differs by 1 to 3 amino acid resides compared to the amino acid sequence of SEQ ID NO: 4; and
(d) a nucleic acid molecule comprising a nucleotide sequence encoding a protein, having insecticidal activity against soybean looper, comprising an amino acid sequence that differs by 1 to 3 amino acid resides compared to the amino acid sequence of SEQ ID NO: 2.
US Pat. No. 10,478,473

COMPOSITIONS AND METHODS OF USING ANTI-MULLERIAN HORMONE FOR TREATMENT OF INFERTILITY

THE CENTER FOR HUMAN REPR...

1. A method for treating infertility in a subject comprising administering to the subject an effective amount of a composition comprising anti-Mullerian hormone (AMH), wherein the AMH comprises the amino acid sequence set forth in SEQ ID NO:1; and wherein the AMH is administered at a dose in the range of about 22,000 ng/day to about 44,000 ng/day for a period of time from about 30 days to about 90 days.
US Pat. No. 10,478,482

VACCINES FOR PREVENTION AND TREATMENT OF TUBERCULOSIS

ALARUM DEVELOPMENT LTD, ...

1. A method of eliciting an immune response against Mycobacterium tuberculosis in a mammalian subject comprising the step of administering to said subject an immunological composition consisting essentially of a first isolated polypeptide of the amino acid sequence of SEQ ID NO: 1, a second isolated polypeptide of the amino acid sequence of SEQ ID NO: 2, and a third isolated polypeptide of the amino acid sequence of SEQ ID NO: 3 and at least one of a pharmaceutically acceptable carrier and an adjuvant.
US Pat. No. 10,480,020

RAPID TEST FOR MICROBIAL RESISTANCES BY MASS SPECTROMETRY

1. Sample support for a mass spectrometric determination of the resistance of a microbial sample to be applied to the sample support, wherein the sample support plate is flat and has on its surface a multiplicity of test sites and at least one test site is coated with a dosed quantity of one or more antibiotics and with one or more reference substances.
US Pat. No. 10,480,031

METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS)

The United States of Amer...

1. A method for producing human retinal pigment epithelial (RPE) cells, comprising:(a) culturing human induced pluripotent stem cells (hiPSCs) in a human embryonic stem cell culture medium comprising human basic fibroblast growth factor (bFGF) and not containing ingredients obtained from non-human animals to produce small embryoid bodies of 200-500 cells;
(b) culturing the small embryoid bodies from step (a) in a first medium comprising retinal induction medium (RIM) and rock inhibitor (RI), wherein the RIM comprises Wnt inhibitor CK1-7, a Nodal pathway inhibitor, Noggin, and 1 to 3% v/v knockout serum replacement, wherein the Nodal pathway inhibitor is SB-431542 or SB-505124, to form embryoid bodies that have increased efficiency of RPE differentiation;
(c) culturing the embryoid bodies that have increased efficiency of RPE differentiation from step (b) on a matrigel coated tissue culture substrate-in a second medium comprising a retinal differentiation medium that does not comprise basic fibroblast growth factor (bFGF) and comprises Dickkopf-related protein 1 (DKK1), CK1-7, a bFGF inhibitor, and Noggin, wherein the bFGF inhibitor is PD0325901, PD98059, PD161570, or PD166285, to form differentiating RPE cells that express PAX6 and MITF;
(d) culturing the differentiating RPE cells from step (C) in a third medium comprising retinal media comprising Activin A and Wnt3a to produce cells that have increased expression of MITF and PAX6 and increased RPE differentiation efficiency; and
(e) culturing the cells that have increased expression of MITF and PAX6 and increased RPE differentiation efficiency from step (d) in a fourth medium comprising a RPE cell medium comprising a non-canonical Wnt 5a inducer, DKK1, SU5402, and cyclopamine to produce human RPE cells that express TYR, TYRP1, MYRIP, Cadherin 1 or Cadherin 3 and TRPMI 1 or TRPMI 3, thereby producing human RPE cells.
US Pat. No. 10,478,497

COMBINATIONS OF INECALCITOL WITH AN ANTI-CD38 AGENT AND THEIR USES FOR TREATING CANCER

HYBRIGENICS S.A., Paris ...

1. The combination of inecalcitol with an anti-CD38 agent, wherein said anti-CD38 agent is selected from the group consisting of daratumumab, isatuximab, and MOR202.
US Pat. No. 10,478,498

EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS

REFORM BIOLOGICS, LLC, W...

1. An injectable, liquid pharmaceutical formulation comprising at least about 100 mg/ml therapeutic protein and a viscosity-reducing amount of caffeine, wherein the viscosity-reducing amount of caffeine is about 15 mg/ml or less, and wherein the formulation further comprises niacinamide, andwherein the viscosity of the formulation is at least about 30% less than the viscosity of a control formulation, wherein the control formulation does not contain caffeine but is otherwise identical on a dry weight basis to the liquid pharmaceutical formulation.
US Pat. No. 10,478,499

ENGINEERED LIGHT-ACTIVATED ANION CHANNEL PROTEINS AND METHODS OF USE THEREOF

The Board of the Trustees...

1. A light-activated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:23, wherein the polypeptide functions as a light-activated anion channel, and wherein the polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acid substitutions selected from A59S, E90S, E101S, E123S, Q117K, H134R, V242K, T246N and N258Q, relative to the amino acid sequence of ChR2 (SEQ ID NO:79).
US Pat. No. 10,478,501

METHOD OF TREATING DISORDERS USING A PHARMACEUTICAL COMPOSITION OF OLIGOPEPTIDES

Merck Patent GmbH, Darms...

1. A method for the treatment of cancer wherein said cancer expresses ?v?3 and/or ?v?5 integrins, comprising a step of subcutaneously and/or intramuscularly administering to a patient who has been identified as having a cancer which expresses ?v?3 and/or ?v?5 integrins an effective amount of a composition which is a suspension comprising:a) 12 to 90% of the oligopeptide cyclo-(Arg-Gly-Asp-DPhe-NMeVal) having a solubility in water at 20° C. between 3 mg/ml and 10 mg/ml,
b) 0.01 to 60% of one or more lipophilic and/or amphiphilic compounds having a molar weight in the range of 200 g/mol to 2000 g/mol, and optionally
c) 0 to 87.99% of water, with the proviso that the sum of a), b) and c) sums up to 80 or more percent of the total composition with the proviso that said suspension composition contains 100 mg/ml or more of said oligopeptide, and with the further proviso that said suspension composition comprises 40% or more of said oligopeptide as solid particles.
US Pat. No. 10,478,503

BRANCHED OLIGONUCLEOTIDES

UNIVERSITY OF MASSACHUSET...

1. A branched oligonucleotide compound, capable of mediating RNA silencing in a neuronal cell, comprising two or more nucleic acid sequences, wherein the nucleic acid sequences (N) are connected to one another by one or more moieties selected from a linker (L), a spacer (S) and optionally a branching point (B),wherein each nucleic acid sequence is double-stranded and comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand each have a 5? end and a 3? end, and wherein the sense strand and the antisense strand each comprises >80% chemically-modified nucleotides,
wherein the nucleotides at positions 1 and 2 from the 5? end of the sense and antisense strands are connected to adjacent nucleotides via phosphorothioate linkages,
wherein each antisense strand comprises at least 15 contiguous nucleotides, wherein each sense strand comprises at least 15 contiguous nucleotides and has complementarity to the antisense strand, and wherein the antisense strand has complementarity to a target mRNA in the neuronal cell, and
wherein the antisense strand is complementary to a target mRNA in a neuronal cell.
US Pat. No. 10,478,504

TAMPER RESISTANT PHARMACEUTICAL FORMULATIONS

PURDUE PHARMA L.P., Stam...

1. A solid oral dosage form comprisinga heat-labile gelling agent;
a thermal stabilizer comprising an anionic polymer in a neutral pH aqueous solution; and
a drug susceptible to abuse,
wherein the solid oral dosage form releases at least about 85% of the drug susceptible to abuse within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml SGF at 37° C.
US Pat. No. 10,478,259

MEDICAL DEVICE PACKAGING WITH POWER SOURCE

BOSTON SCIENTIFIC SCIMED,...

1. A system for charging an onboard battery of a medical device prior to use of the medical device, the system comprising:a package defining a first cavity and a second cavity spaced apart from the first cavity;
a medical device disposed within the first cavity of the package, the medical device including an onboard rechargeable battery disposed within the medical device; and
a power source disposed within the second cavity of the package and capable of charging the onboard battery of the medical device prior to use of the medical device;
a controller disposed within the package and configured to use power stored within the power source to charge the onboard rechargeable battery disposed within the medical device prior to use of the medical device, the controller further configured to periodically check a power level within the onboard rechargeable battery and to recharge the onboard rechargeable battery when the power level of the onboard rechargeable battery drops below a threshold in order to maintain the medical device in a ready to use condition;
the system capable of being subjected to a sterilization process with the power source disposed within the second cavity.
US Pat. No. 10,478,531

METHODS AND MATERIALS FOR TREATING BLOOD VESSELS

1. An angioplasty balloon catheter comprising a stent-less angioplasty balloon coated with an amnion tissue preparation.
US Pat. No. 10,479,814

ADENOSINE RECEPTOR ACTIVATION REAGENT AND THE USES OF THEREOF

Zhejiang Subtropical Crop...

1. A method for treating a condition comprising administering N(6)-(2-hydroxyethyl)-adenosine (HEA) to a subject, wherein the condition is convulsion, pain, apoplexia, Parkinson's disease, or opioid drug addiction receptor; said HEA is administered in the amount of 10-15 mg/kg of subject body weight and treats the condition via the adenosine A1 receptor.
US Pat. No. 10,479,817

TEMPLATES FOR CONTROLLING SYNTHESIS OF NANOPARTICLES INTO DISCRETE ASSEMBLIES

1. A nanostructure comprising: (a) a conjugate molecule comprising a biomineralization peptide attached chemically at its N-terminus to a self-associating moiety, wherein the self-associating moiety is selected from a linear aliphatic carbon chain and an aromatic organic group; and (b) a nanoparticle comprising a metal or semiconductor element; wherein the biomineralization peptide binds to the metal or semiconductor element of the nanoparticle.
US Pat. No. 10,478,800

HIGHLY ORDERED TITANIA NANOTUBE ARRAYS FOR PHOSPHOPROTEOMICS

UNIVERSITY OF HOUSTON SYS...

1. A device for isolation of phosphopeptides in a sample, comprising:an ordered TiO2 nanotube array comprising ordered TiO2 nanotubes grown on a Ti surface, wherein the nanotubes point outward from the Ti surface, wherein the Ti surface is a Ti wire, and wherein the nanotubes point radially outward from the Ti wire; and
a container for phosphopeptide isolation, wherein the ordered TiO2 nanotube array is located within the container, and wherein the sample is placed in the container to contact the ordered TiO2 nanotube array.
US Pat. No. 10,479,825

ANTIBODY-MEDIATED NEUTRALIZATION OF MARBURG VIRUS

VANDERBILT UNIVERSITY, N...

1. An engineered cell producing an antibody or antibody fragment characterized by heavy chain CDR sequences of SEQ ID NOS: 104, 105 and 106 and light chain CDR sequences of SEQ ID NO: 150, DNN and SEQ ID NO: 151.
US Pat. No. 10,478,801

PROCESS FOR OBTAINING ADSORBENT MATERIAL BASED ON POROUS SILICATES FOR REDUCTION OF SULFUR AND NITROGEN IN OIL FRACTIONS

INSTITUTO MEXICANO DEL PE...

1. A process for reducing a sulfur and nitrogen content of a petroleum fraction or product derived therefrom, comprising the steps of:contacting the petroleum fraction or product derived therefrom with a porous silicate adsorbent containing at least one metal selected from the group consisting of Cu, Ni, Sn, Fe, Ag, Co, Ti, V, Cr, and Mn; and
adsorbing and removing sulfur and/or nitrogen compounds from said petroleum fraction or product derived therefrom.
US Pat. No. 10,479,060

CONCEALABLE FILM, LAMINATE, AND PACKAGING MATERIAL

Unitika Ltd., Hyogo (JP)...

11. A concealable film wherein on at least one surface of a layer A comprising 1 to 40% by mass of an amorphous polyamide resin, 10 to 60% by mass of titanium oxide and 0 to 89% by mass of a crystalline polyamide resin, with a proviso that the total content of these is 100% by mass, the crystalline polyamide resin being one selected from a group consisting of nylon 6 and polymetaxylylene adipamide, the amorphous polyamide resin including terephthalic acid and isophthalic acid as a dicarboxylic acid component and hexamethylenediamine and 4,4?-diamino-3,3?-dimethyl-dicyclohexylene methane as a diamine component, a layer B constituted with a polyamide resin and not including titanium oxide is laminated, the polyamide resin constituting the layer B including 80% or more by mass of nylon 6, the concealable film being stretched and having a thickness of 10 to 30 ?m and the concealable film having a multilayer structure that is one of B/A/B and B/A/B/A/B wherein each layer A directly contacts each layer B.
US Pat. No. 10,479,830

ANTI EOTAXIN-2 ANTIBODIES THAT RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES

CHEMOMAB LTD., Tel Aviv ...

1. An isolated antibody that binds a conformational epitope in the N-loop region of a CCR3-binding chemokine, wherein said conformational epitope is characterized by a relatively high concentration of positive amino acid residues located between amino acid positions 14 and 24 in the amino acid sequence of said CCR3-binding chemokine as denoted by SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 14 and wherein said antibody is a fully humanized antibody comprising a heavy chain variable region comprising:a) the complementary determining region VH CDR1 comprising the amino acid sequence denoted by SEQ ID NO. 5;
b) the complementary determining region VH CDR2 comprising the amino acid sequence denoted by SEQ ID NO. 6; and
c) the complementary determining region VH CDR3 comprising the amino acid sequence denoted by SEQ ID NO. 7; and
a light chain variable region comprising
d) the complementary determining region VK CDR1 comprising the amino acid sequence denoted by SEQ ID NO. 8;
e) the complementary determining region VK CDR2 comprising the amino acid sequence denoted by SEQ ID NO. 9; and
f) the complementary determining region VK CDR3 comprising the amino acid sequence denoted by SEQ ID NO. 10.
US Pat. No. 10,479,831

BCR-COMPLEX-SPECIFIC ANTIBODIES AND METHODS OF USING SAME

MacroGenics, Inc, Rockvi...

1. A method of treating an autoimmune or immune-mediated inflammatory disease in a subject, comprising administering to said subject a therapeutically effective amount of a diabody that binds human BCR complex, wherein said diabody comprises:(I) an amino acid sequence of an immunoglobulin light chain variable region (VL) that is a humanized variant of BCC VL that comprises:
(A) a modification at Kabat residue 37;
(B) a modification at Kabat residue 45; or
(C) both (A) and (B); and
(II) an amino acid sequence of an immunoglobulin heavy chain variable region (VH) that is a humanized variant of BCC VH that comprises a modification of one or more of Kabat residues 48, 62, 66, 67, 68, 69, 70, 71 or 73.
US Pat. No. 10,477,787

METHOD TO IDENTIFY ASIAN SOYBEAN RUST RESISTANCE QUANTITATIVE TRAIT LOCI IN SOYBEAN AND COMPOSITIONS THEREOF

Monsanto Technology LLC, ...

1. A method for producing an Asian Soybean Rust (ASR) resistant soybean plant, said method comprising:selecting a soybean plant using marker assisted selection from a plurality of soybean plants derived from an ASR resistant soybean plant comprising ASR resistance locus 16 by detecting a molecular marker that is within 10 centimorgans or less from a resistance allele of a SNP marker selected from the group consisting of NS0113966 and NS0118536;
obtaining a seed from said selected plant, and
generating from said obtained seed an ASR-resistant progeny plant comprising said resistance allele.
US Pat. No. 10,477,792

TOMATO HYBRID SV0599TM

Seminis Vegetable Seeds, ...

1. A tomato plant of tomato hybrid SV0599TM, a sample of seed of said hybrid SV0599TM having been deposited under ATCC Accession Number PTA-121395.
US Pat. No. 10,477,793

TOMATO LINE FIRKL13-4132

Seminis Vegetable Seeds, ...

1. A tomato plant comprising at least a first set of the chromosomes of tomato line FIRKL13-4132, a sample of seed of said line having been deposited under ATCC Accession Number PTA-122113.
US Pat. No. 10,479,847

POLYMER-ENCAPSULATED PIGMENT PARTICLE

SWIMC LLC, Cleveland, OH...

1. A pigment grind dispersion comprising a mixture of:a) a carrier comprising water;
b) opacifying inorganic pigment particles having an index of refraction of at least 1.8 and being at least partially encapsulated by at least one polymer layer;
c) alkali; and
d) a polymeric dispersing agent having one or more alkali-swollen or alkali-dissolved copolymer components, wherein the alkali-swollen or alkali-dissolved component is derived from ingredients including one or more ethylenically unsaturated hydrophilic monomers that include a hydroxyl group, acidic group, amino group or ethylene oxide group, and the polymeric dispersing agent is present at about 0.1 to about 25 wt. % of the opacifying pigment particle weight.
US Pat. No. 10,477,795

COTTON VARIETY PX499096W3FE

Phytogen Seed Company, LL...

1. A seed of cotton variety designated PX499096W3FE, or a regenerable part thereof, representative seed of the variety having been deposited under ATCC Accession No. PTA-123655 on Nov. 15, 2016.